NCT07573917Recruiting
Improving Insulin Sensitivity in Patients With Type 2 Diabetes Via Repeated Cold-induced Shivering Thermogenesis
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Type 2 Diabetes Mellitus (T2DM) is a widespread health condition characterized by impaired ability of the body to maintain glucose homeostasis. This impairment often leads to secondary complications, including heart disease, high blood pressure, and poor quality of life. While exercise and healthy eating are effective strategies in managing and preventing T2DM, data shows that long-term adherence to these methods are poor - especially among elderly, individuals with obesity and/or with physical limitations. This clinical study explores cold exposure with shivering as a novel strategy to improve blood sugar control and heart health. In earlier research, spending time in mildly cold environments (around 15-17°C) for a few hours a day improved insulin sensitivity of T2DM patients. Interestingly, these benefits only occurred when the cold caused mild shivering. In a recent 10-day cold acclimation study with overt shivering for minimally 1 hour/day, we observed improved glucose tolerance in participants with overweight/obesity, as well as improved fasting lipid profiles. These results indicate that when accompanied with sufficient level of muscle activation, repeated exposure to cold can beneficially affect both glucose and lipid levels - both of which are impaired in people with T2DM. In this study, we hypothesise that a 10-day cold acclimation with shivering will improve the (peripheral) insulin sensitivity of patients with T2DM, accompanied by enhanced skeletal muscle FA uptake and oxidation as assessed via the 11C palmitate uptake.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 9 Sept 2025
- Start date
- 24 Sept 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- Université de Sherbrooke
- Diseases
- Type 2 diabetes
- NCT number
- NCT07573917
What you commit to
- Study type: Interventional
- Planned participants: 15
- From 24 Sept 2025 to the primary completion date, 31 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous enrolment in a clinical study with an investigational product during the last 3 months or as judged by the Investigator
- Being insulin-dependent and/or using SGLT2 inhibitor medications
- A medical doctor will judge participation eligibility based on the medical history questionnaire, medication use and fasting blood parameters. If the medical doctor advises that a patient cannot participate, the patient will be excluded from enrolment.
Other illness
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency
Lab values
- Men: Hb \<8.4 mmol/L, Women: Hb \<7.8 mmol/l
Other
- Participate in sports of physical activity at a moderate- to high-intensity more than 3 times a week, or as judged by the investigator
- Being cold-acclimated, e.g. having taken daily extended cold baths, working in a refrigerated environment, or practicing regular cold-water swimming/ showering within 1 month of starting the study
- Unstable body weight (weight gain or loss \> 5 kg in the last three months)
- Alcohol consumption of \>2 servings per day for man and \>1 servings per day for women
- Smoking
- Being pregnant
- Having participated in another study involving PET/CT scanning in the past 1 year
Who the study is looking for
- Patients are able to provide signed and dated written informed consent prior to any study specific procedures
- Women are post-menopausal (defined as at least 1 year post cessation of menses)
- Aged ≥ 40 years and ≤ 75 years
- Patients should have suitable veins for cannulation or repeated venipuncture
- Body mass index (BMI) 25-38 kg/m2
- Stable dietary habits (no weight loss or gain \>5kg in the past 3 months)
- Diagnosed with T2D at least 1.5 years before the start of the study
- Relatively well-controlled T2D: HbA1c \< 8.5%
- Oral glucose-lowering medication: metformin alone or in combination with sulfonylurea agents and/or on stable dose of a DPPIV inhibitor treatment for at least the last 3 months. In case of GLP-1 agonist medication treatment inclusion will be discussed with the dependent physician.
- No signs of active diabetes-related co-morbidities like active cardiovascular diseases, active diabetic foot, polyneuropathy or retinopathy
- No signs of active liver or kidney malfunction
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre de recherche du CHUS Coordinator of this site? Confirm its status | Sherbrooke | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.